SuperValu Inc. (SVU) on Tuesday reported fiscal first-quarter profit of $61 million.
Advertisement
The results surpassed Wall Street expectations.
“We’re investing resources to grow our strongest brands and to support the most promising assets in our pipeline, while at the same time lowering our overall cost base”, he told analysts during a conference call. Sales declined in cardiovascular and Hepatitis C, the company stated.
We’re witnessing the introduction of breakthrough therapies for some of the most difficult-to-treat diseases.
Merck agreed to acquire cCAM Biotherapeutics, a privately held biopharmaceutical company focused on the discovery and development of novel cancer immunotherapies. Keytruda also is in that growing new class of drugs, which use different mechanisms to boost the immune stystem and help it fight cancer. The company has a market cap of $161,009 million and the number of outstanding shares have been calculated to be 2,825,222,000 shares.
Merck & Co Inc (MRK.N) indicated an nearly 11 % decrease in per quarter revenue now being a solid dollar plus the deal of the end user worry business venture obscured solid involve its diabetes prescription medications.
The latest reported quarter included charges of $1.45 billion related to its acquisition of Cubist Pharmaceuticals.
The company also said it expects to reap benefits from its $8.4 billion purchase of Cubist Pharmaceuticals, the maker of blockbuster antibiotic Cubicin.
Total sales fell to $9.76 billion from $10.93 billion the year before.
Remicade had sales of $455 million, down 25%.
Sales of top product Januvia edged up 1 percent to $1.6 billion, while sales rose 4 percent to $427 million for Gardasil, which protects against sexually transmitted cancers, and 10 percent to a total of $358 million for all its other vaccines. Excluding non-recurring items, the company’s adjusted earnings came in at $0.86 per share.
Advertisement
The average estimate among 39 Estimize users was for earnings of $0.81 per share and revenue of $9.74 billion.
